Diazon Pharmaceuticals

Diazon Pharmaceuticals Overview

  • Founded
  • 2013
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 1

Diazon Pharmaceuticals General Information


Developer of onco-therapeutic drugs intended to target a proven therapeutic pathway in oncology. The company's drugs offer an anti cancer agent, which modulates micro-tubule structure and dynamics in a distinct way, delivering potent anti-tumor efficacy with an unusually safety profile, including lack of neurotoxicity in pre-clinical models, enabling clinicians to kill cancer cells with improved safety margins compared to the other micro-tubule targeting agents.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 1010 Sherbrooke Street West
  • Suite 408
  • Montreal, Quebec H3A 2R7
  • Canada
+1 (514) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Diazon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Generating Revenue

Diazon Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Louise Proulx Ph.D Chief Development Officer & Board Member
Pierre Beauparlant Ph.D Chief Business Officer
Michael Dixon Chief Financial Officer, Interim President & Board Member
Gordon Shore Ph.D Co-Founder & Chief Scientific Officer
Patrick Harran Ph.D Co-Founder

1 Former Executive

Diazon Pharmaceuticals Board Members (3)

Name Representing Role Since
Louise Proulx Ph.D Diazon Pharmaceuticals Chief Development Officer & Board Member 000 0000
Michael Dixon Self Chief Financial Officer, Interim President & Board Member 000 0000
Robert Mcneil Ph.D Sanderling Ventures Chairman 000 0000

Diazon Pharmaceuticals Investors (1)

To view Diazon Pharmaceuticals‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sanderling Ventures Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial